RU2014132706A - Нуклеиновые кислоты, специфически связывающие cgrp - Google Patents
Нуклеиновые кислоты, специфически связывающие cgrp Download PDFInfo
- Publication number
- RU2014132706A RU2014132706A RU2014132706A RU2014132706A RU2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A
- Authority
- RU
- Russia
- Prior art keywords
- nucleic acid
- seq
- acid molecule
- molecule according
- cgrp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/000089 WO2012095303A1 (en) | 2011-01-10 | 2012-01-10 | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
| EPPCT/EP2012/000089 | 2012-01-10 | ||
| EP12000105.2 | 2012-01-10 | ||
| EP12000105 | 2012-01-10 | ||
| PCT/EP2013/000055 WO2013104539A1 (en) | 2012-01-10 | 2013-01-10 | Nucleic acids specifically binding cgrp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014132706A true RU2014132706A (ru) | 2016-02-27 |
Family
ID=48781062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014132706A RU2014132706A (ru) | 2012-01-10 | 2013-01-10 | Нуклеиновые кислоты, специфически связывающие cgrp |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9163243B2 (enExample) |
| EP (1) | EP2802659A1 (enExample) |
| JP (1) | JP2015506174A (enExample) |
| KR (1) | KR20140111704A (enExample) |
| CN (1) | CN104136612A (enExample) |
| AU (1) | AU2013209130A1 (enExample) |
| BR (1) | BR112014016939A2 (enExample) |
| CA (1) | CA2860809A1 (enExample) |
| HK (1) | HK1198370A1 (enExample) |
| IL (1) | IL233515A0 (enExample) |
| MX (1) | MX2014008456A (enExample) |
| RU (1) | RU2014132706A (enExample) |
| SG (1) | SG11201403769YA (enExample) |
| WO (1) | WO2013104539A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2815444C2 (ru) * | 2018-11-12 | 2024-03-15 | Аптарион Биотех Аг | Cxcl8-связывающие нуклеиновые кислоты |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9518265B2 (en) | 2012-01-10 | 2016-12-13 | Noxxon Pharma Ag | C5a binding nucleic acids |
| MX378344B (es) | 2014-03-21 | 2025-03-10 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. |
| JP6584868B2 (ja) * | 2015-02-25 | 2019-10-02 | 学校法人 関西大学 | ゲル素材及びその製造方法 |
| EA201890578A1 (ru) * | 2015-09-24 | 2018-12-28 | Тева Фармасьютикалз Интернэшнл Гмбх | Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли |
| ES2607639B1 (es) | 2015-09-30 | 2018-02-28 | Urquima, S.A | Sal de ácido maleico de un intermedio de silodosina |
| AU2017331593B2 (en) | 2016-09-23 | 2022-04-28 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| CN113383079B (zh) | 2018-11-12 | 2024-11-19 | 阿普塔里恩生物技术股份公司 | Cxcl8结合性核酸 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US6682886B1 (en) | 1994-04-28 | 2004-01-27 | Gilead Sciences, Inc. | Bivalent binding molecules of 7 transmembrane G protein-coupled receptors |
| WO1996005221A1 (en) | 1994-08-16 | 1996-02-22 | Human Genome Sciences, Inc. | Calcitonin receptor |
| JP4531132B2 (ja) | 1995-06-02 | 2010-08-25 | ギリード・サイエンシズ・インコーポレーテッド | 増殖因子に対する高親和性オリゴヌクレオチドリガンド |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| RU2180311C1 (ru) | 2001-07-05 | 2002-03-10 | Мешалкин Георгий Алексеевич | Защитная пробка |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| DK2431377T3 (en) | 2001-10-26 | 2017-08-14 | Noxxon Pharma Ag | Modified L-nucleic acids |
| ATE441706T1 (de) | 2002-02-20 | 2009-09-15 | Gen Hospital Corp | Konjugate mit biologisch abbaubarem polymer und verwendung dafür |
| WO2003093472A2 (de) * | 2002-05-06 | 2003-11-13 | Grünenthal GmbH | Cgrp bindende nukleinsäuren |
| MXPA05011022A (es) | 2003-04-13 | 2006-04-27 | Enzon Pharmaceuticals Inc | Profarmacos oligonucleotidos polimericos. |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| US20090281296A1 (en) | 2004-02-09 | 2009-11-12 | Supramol Parenteral Colloid Gmbh | Process for the production of conjugates from polysaccharides and polynucelotides |
| WO2005099768A2 (en) | 2004-03-23 | 2005-10-27 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
| CA2585664C (en) | 2004-11-05 | 2014-05-20 | The Children's Hospital Of Philadelphia | Biodegradable linkers for molecular therapies |
| EP1877069A2 (de) * | 2005-05-04 | 2008-01-16 | Noxxon Pharma AG | Neue verwendung von spiegelmeren |
| MX2009002859A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
| EP2061901A2 (en) | 2006-10-31 | 2009-05-27 | Noxxon Pharma AG | Methods for detection of a single- or double-stranded nucleic acid molecule |
| EP2561079A1 (en) | 2010-04-21 | 2013-02-27 | Noxxon Pharma AG | Lipid binding nucleic acids |
| EP2663640B1 (en) * | 2011-01-10 | 2020-11-04 | APTARION biotech AG | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
-
2013
- 2013-01-10 BR BR112014016939A patent/BR112014016939A2/pt not_active IP Right Cessation
- 2013-01-10 HK HK14111873.3A patent/HK1198370A1/xx unknown
- 2013-01-10 JP JP2014551569A patent/JP2015506174A/ja active Pending
- 2013-01-10 SG SG11201403769YA patent/SG11201403769YA/en unknown
- 2013-01-10 WO PCT/EP2013/000055 patent/WO2013104539A1/en not_active Ceased
- 2013-01-10 EP EP13700455.2A patent/EP2802659A1/en not_active Withdrawn
- 2013-01-10 AU AU2013209130A patent/AU2013209130A1/en not_active Abandoned
- 2013-01-10 CN CN201380009019.6A patent/CN104136612A/zh active Pending
- 2013-01-10 MX MX2014008456A patent/MX2014008456A/es unknown
- 2013-01-10 CA CA2860809A patent/CA2860809A1/en not_active Abandoned
- 2013-01-10 KR KR1020147022328A patent/KR20140111704A/ko not_active Withdrawn
- 2013-01-10 US US14/371,210 patent/US9163243B2/en not_active Expired - Fee Related
- 2013-01-10 RU RU2014132706A patent/RU2014132706A/ru not_active Application Discontinuation
-
2014
- 2014-07-03 IL IL233515A patent/IL233515A0/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2815444C2 (ru) * | 2018-11-12 | 2024-03-15 | Аптарион Биотех Аг | Cxcl8-связывающие нуклеиновые кислоты |
Also Published As
| Publication number | Publication date |
|---|---|
| US9163243B2 (en) | 2015-10-20 |
| CN104136612A (zh) | 2014-11-05 |
| CA2860809A1 (en) | 2013-07-18 |
| BR112014016939A2 (pt) | 2019-09-24 |
| US20150031755A1 (en) | 2015-01-29 |
| JP2015506174A (ja) | 2015-03-02 |
| SG11201403769YA (en) | 2014-07-30 |
| EP2802659A1 (en) | 2014-11-19 |
| AU2013209130A1 (en) | 2014-07-10 |
| IL233515A0 (en) | 2014-08-31 |
| MX2014008456A (es) | 2014-11-25 |
| HK1198370A1 (en) | 2015-04-10 |
| KR20140111704A (ko) | 2014-09-19 |
| WO2013104539A1 (en) | 2013-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014132708A (ru) | НОВЫЕ СВЯЗЫВАЮЩИЕ C5a НУКЛЕИНОВЫЕ КИСЛОТЫ | |
| DE69637430T2 (de) | Neue opioid peptide, selektiv für kappa rezeptor | |
| JP2015506174A5 (enExample) | ||
| JP2013524792A5 (enExample) | ||
| Suat et al. | Design of β-turn based therapeutic agents | |
| AU2024202618A1 (en) | Bicyclic peptide ligands specific for EphA2 | |
| Bigoni et al. | Nociceptin/orphanin FQ receptor ligands | |
| Ung et al. | Tripeptide motifs in biology: targets for peptidomimetic design | |
| JP2014533098A5 (enExample) | ||
| DE69212914T2 (de) | Schnellsynthese und Screening von Peptidmimetika | |
| CN1826353A (zh) | 新的黑皮质素受体模板、肽及其用途 | |
| Todorov et al. | Synthesis, characterization and nociceptive screening of new VV-hemorphin-5 analogues | |
| Romero et al. | Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective μ/κ antagonist in the [35S]‐GTP‐γ‐S functional binding assay | |
| Li et al. | Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to β-endorphin? | |
| Sluka et al. | Reagents and methods for the solid-phase synthesis of protein-EDTA for use in affinity cleaving | |
| Harris et al. | Antinociceptive activity of thiazole-containing cyclized DAMGO and Leu-(Met) enkephalin analogs | |
| WO1994026296A1 (en) | Novel opioid peptide inhibitors | |
| US7144986B2 (en) | Polypeptides comprising IL-6 ligand binding receptor domains | |
| CN118221772A (zh) | 一种μ-芋螺毒素结构优化的突变体及其应用 | |
| EP2328925A1 (en) | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | |
| ZA200407103B (en) | Anti-infarction molecules | |
| JP4275738B2 (ja) | 神経刺激性ペプチド | |
| US20080194467A1 (en) | Cancer treatment methods using cadherin antagonists in combination with anticancer agents | |
| DE4427980A1 (de) | Nukleinsäuren-bindende Oligomere für Therapie und Diagnostik | |
| Haaseth et al. | [L-Ala3] DPDPE: A New Enkephalin Analog with a Unique Opioid Receptor Activity Profile. Further Evidence of. delta.-Opioid Receptor Multiplicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170403 |